Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Pediatric Brain Tumor Consortium
Modality
gene_therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04482933CT.gov HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Giant Cell Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| g207 (this asset) | Pediatric Brain Tumor Consortium | P2 | CCC · 53 |
| Irinotecan | Case Comprehensive Cancer Center | P2 | BBB |
| Cediranib | Lawrence Recht | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Rindopepimut | Celldex Therapeutics | P3 | BB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Giant Cell Glioblastoma cohort
Other indications for g207
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Glioma | — | P2 | CCC · 53 |
| Glioblastoma | — | P2 | CCC · 53 |
| Brain Glioma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanCase Comprehensive Cancer CenterBBB
- CediranibLawrence RechtBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- SorafenibNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. g207 in Giant Cell Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/g207-giant-cell-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →